CG Oncology Inc. (NASDAQ: CGON) announced positive results from its CORE-008 Cohort CX Phase 2 trial evaluating an intravesical combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE